Advertisement

Topics

Lonza Inc. Company Profile

22:15 EST 10th December 2018 | BioPortfolio

Basel, 17.05.2006 - Lonza Group announces the acquisition of assets which comprise Larex, Inc.’s Larch Arabinogalactan business. This strategic acquisition includes among other things, intellectual property, proprietary processing technology, manufacturing operations in Cohasset, Minnesota (USA), certain inventory and customer lists. Larex, Inc. is the exclusive North American vertically integrated manufacturer of the nutritional compound Larch Arabinogalactan (“LAG”), a natural soluble fiber extracted from harvested Larch trees. LAG is extracted and purified through a patented and proprietary process to deliver functionally optimized products sold into the health science, consumer and industrial markets.
LAG, a natural, bioactive compound for use in human and animal nutrition, personal care and industrial applications, is generally recognized as safe (GRAS). It has been found to offer many significant benefits, the most important ones being in the fields of immune enhancement and digestive health. LAG products provide multifunctional properties either in stand-alone products or when combined with other ingredients to enhance product performance.

With the acquisition of Larch Arabinogalactan, Lonza further expands its portfolio of nutrition businesses within Organic Fine & Performance Chemicals. This Lonza division thus continues to actively broaden its innovative offerings and complements the existing product line.

Location

90 Boroline Rd.
Allendale
New Jersey
United States of America

Contact

Phone: 1 201 316 9200
Fax: 1 201 785 9989
Email: agsales@lonza.com


News Articles [97 Associated News Articles listed on BioPortfolio]

Lonza to establish strategic biomanufacturing base in China using GE Healthcare solution

Lonza announces an agreement with GE Healthcare under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou (CN)

Lonza sells water care business to focus on healthcare

Lonza and Platinum Equity jointly announced today that Platinum Equity has entered into a definitive agreement with Lonza to acquire Lonza's Water Care business and operations for USD 630 million. The...

Lonza and Sartorius Modify Relationship for Supply of Cell Culture Media

NewsSartorius Stedim Biotech, as a preferred supplier for equipment and consumables, will continue to offer Lonza media and buffer products, but under a non-exclusive agreement.

Lonza to establish China base through GE Healthcare partnership

Biotechnology company Lonza has announced an initiative with GE Healthcare in which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou, China (CN).

Sartorius Stedim and Lonza Modify Supply Pact

Biopharmaceutical supplier Sartorius Stedim Biotech and fine chemicals producer Lonza are modifying their 2012 agreement for supply of cell culture media, which gave SSB exclusive sales and marketing ...

Lonza and Clovis Open New Monoplant for Ovarian Cancer Drug

Lonza and Clovis Oncology have opened a new, dedicated production train for Rubraca (rucaparib), at Lonza’s Visp site in Switzerland. Rubraca is Clovis’ US- and EU-approved drug for severa...

Lonza Launches New Bioscience Website

Lonza Bioscience is inviting visitors to explore its new dedicated website: bioscience.lonza.com. Filled with detailed application and product information, the website has been designed to support the...

Lonza boosts ADC manufacturing with new investment

Antibody-drug conjugates have occupied a corner of the biologic market for years. Lonza, though, is betting on faster growth.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

LONZA Biologics plc

Lonza is continually expanding its scientific and technology base, assigning a high priority to advanced R&D as well as state-of the-art plants and equipment to ensure environmentally safe and quality...

Lonza Group Ltd

Lonza is continually expanding its scientific and technology base, assigning a high priority to advanced R&D as well as state-of the-art plants and equipment to ensure environmentally safe and quality...

Lonza Inc.

Basel, 17.05.2006 - Lonza Group announces the acquisition of assets which comprise Larex, Inc.’s Larch Arabinogalactan business. This strategic acquisition includes among other things, intellectual...

Akouos

Akouos is a precision genetic medicine company developing gene therapies that restore and preserve hearing. Leveraging its adeno-associated viral vectors (AAV)-based gene therapy ...

Microbe Inotech Laboratories, Inc.

Microbe Inotech Laboratories, Inc. was founded in 1991. Dr. Bruce C. Hemming started the company after ten years of progressively advanced experience at Monsanto Company. His career included research ...

More Information about "Lonza Inc." on BioPortfolio

We have published hundreds of Lonza Inc. news stories on BioPortfolio along with dozens of Lonza Inc. Clinical Trials and PubMed Articles about Lonza Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lonza Inc. Companies in our database. You can also find out about relevant Lonza Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record